Stockholm, Sweden – April 26 2024 – OncoZenge AB (publ), a leading pharmaceutical company developing BupiZenge™, an innovative, non-opioid treatment for oral pain, today announces the appointment of Anna Asplind as Phase 3 Program Manager.As previously communicated the OncoZenge strategy and focus.
Enzymatica AB: Enzymatica Interim report Q1/2024: MDR certification opens up great commercial opportunities finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ First quarter Net sales reached SEK 9.4 (13.0) million. The operating result totaled SEK -18.4 (-14.4) million. Earnings per share, basic and.